Skip to Content

Investor Alert From Cauley Bowman Carney & Williams, PLLC: Update on Proposed Acquisition of Bradley Pharmaceuticals, Inc. - BDY

LITTLE ROCK, Ark., May 30, 2007 /PRNewswire/ -- Cauley Bowman Carney & Williams, PLLC announces an investigation into the proposed acquisition of Bradley Pharmaceuticals, Inc. ("Bradley"). On May 29, 2007, Bradley announced that it had received a buyout offer from an investment group led by Chief Executive Daniel Glassman. Under the terms of the proposal, Bradley shareholders would receive $21.50 per share in cash for each share owned. This price per share represents a 17% premium over the stock's closing price prior to announcement of the merger. The company's current stock price is over 4% above the proposed offer. If the proposed merger is completed, Bradley will no longer be a publicly traded company.

Cauley Bowman Carney & Williams, PLLC

Cauley Bowman is a national law firm that represents investors in securities fraud and corporate governance class actions. It is one of the country's premier firms in the area of securities fraud having recovered billions of dollars for defrauded investors and secured significant corporate governance reforms. Cauley Bowman maintains in-house finance, forensic accounting specialists and extensive trial experience.

If you are a current shareholder of Bradley Pharmaceuticals, Inc. and would like to be advised of your rights in this matter, you may contact Cauley Bowman Carney & Williams, PLLC at the phone number below.


    Darrin L. Williams, Esq.

    Randall K. Pulliam, Esq.


CONTACT: Kristi Gray of Cauley Bowman Carney & Williams, PLLC,+1-501-312-8500

Web site:

Ticker Symbol: (:BDY)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

Posted: May 2007